A 72-year-old man with biopsy-proven prostate cancer (Gleason 9, PSA 45 ng/mL, clinical stage T3b) undergoes staging CT and bone scan, which reveal multiple osteoblastic lesions in the lumbar spine and pelvis. He is asymptomatic from his metastases. What is the most appropriate next step in management?

Explanation

## Clinical Scenario This patient has **metastatic castration-naive prostate cancer** (mCSPC) with high-volume disease (Gleason 9, PSA 45, multiple bone metastases). The presence of metastases mandates systemic therapy, not local treatment. ## Metastatic Prostate Cancer Management **Key Point:** Newly diagnosed metastatic prostate cancer requires immediate systemic therapy with ADT. In high-volume disease, addition of docetaxel improves overall survival. **High-Yield:** High-volume metastatic disease is defined by: - Visceral metastases (liver, lung, peritoneal), OR - ≥4 bone lesions with ≥1 beyond pelvis/lumbar spine This patient has ≥4 bone lesions (lumbar spine and pelvis), meeting high-volume criteria. ## Treatment Algorithm for mCSPC ```mermaid flowchart TD A[Metastatic Castration-Naive Prostate Cancer]:::outcome --> B{Volume of Disease?}:::decision B -->|High-volume| C[ADT + Docetaxel]:::action B -->|Low-volume| D[ADT ± Docetaxel]:::action C --> E[Assess response at 3-4 months]:::decision D --> E E -->|PSA decline + clinical response| F[Continue ADT]:::action E -->|Progression| G[Switch to next-generation AR inhibitor]:::action ``` ## Why ADT + Docetaxel? | Agent | Mechanism | Benefit in High-Volume Disease | | --- | --- | --- | | **ADT (GnRH agonist/antagonist)** | Reduces serum testosterone to castrate levels | Standard of care; reduces PSA and tumor burden | | **Docetaxel** | Microtubule-stabilizing chemotherapy | Improves OS by ~13 months in high-volume mCSPC (CHAARTED trial) | **Clinical Pearl:** The CHAARTED trial (2015) demonstrated that docetaxel + ADT improves overall survival compared to ADT alone in high-volume metastatic disease. This is now standard of care. **Mnemonic: CHAARTED** — **C**hemotherapy **H**elps **A**dvanced **A**ndrogen-**R**esponse **T**reatment **E**arly **D**isease. ## Why Other Options Are Wrong - **Palliative radiotherapy alone:** Appropriate for bone pain or spinal cord compression, but does not address systemic disease and is not first-line. - **Observation:** Metastatic disease requires immediate treatment; delay worsens prognosis. - **Radical prostatectomy:** Contraindicated in metastatic disease; surgery cannot cure disseminated cancer and exposes patient to unnecessary morbidity. [cite:Harrison 21e Ch 182; NCCN Prostate Cancer Guidelines 2023]